JP2018529779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529779A5 JP2018529779A5 JP2018536704A JP2018536704A JP2018529779A5 JP 2018529779 A5 JP2018529779 A5 JP 2018529779A5 JP 2018536704 A JP2018536704 A JP 2018536704A JP 2018536704 A JP2018536704 A JP 2018536704A JP 2018529779 A5 JP2018529779 A5 JP 2018529779A5
- Authority
- JP
- Japan
- Prior art keywords
- milligrams
- composition
- therapeutically effective
- effective amount
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 11
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 11
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 11
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 7
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 23
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 2
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- -1 keto fatty acid Chemical class 0.000 description 3
- WRADPCFZZWXOTI-BMRADRMJSA-N (9E)-10-nitrooctadecenoic acid Chemical compound CCCCCCCC\C([N+]([O-])=O)=C/CCCCCCCC(O)=O WRADPCFZZWXOTI-BMRADRMJSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- CQOAKBVRRVHWKV-SAPNQHFASA-N (9E)-9-nitrooctadecenoic acid Chemical compound CCCCCCCC\C=C([N+]([O-])=O)/CCCCCCCC(O)=O CQOAKBVRRVHWKV-SAPNQHFASA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 230000002783 anti-lipogenic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021139287A JP2021183640A (ja) | 2015-10-02 | 2021-08-27 | 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236702P | 2015-10-02 | 2015-10-02 | |
| US62/236,702 | 2015-10-02 | ||
| PCT/US2016/055206 WO2017059451A1 (en) | 2015-10-02 | 2016-10-03 | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021139287A Division JP2021183640A (ja) | 2015-10-02 | 2021-08-27 | 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529779A JP2018529779A (ja) | 2018-10-11 |
| JP2018529779A5 true JP2018529779A5 (https=) | 2019-11-14 |
Family
ID=58428002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536704A Withdrawn JP2018529779A (ja) | 2015-10-02 | 2016-10-03 | 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転 |
| JP2021139287A Pending JP2021183640A (ja) | 2015-10-02 | 2021-08-27 | 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021139287A Pending JP2021183640A (ja) | 2015-10-02 | 2021-08-27 | 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10537541B2 (https=) |
| EP (1) | EP3355879A4 (https=) |
| JP (2) | JP2018529779A (https=) |
| KR (1) | KR20180098222A (https=) |
| CN (2) | CN108430466A (https=) |
| AU (2) | AU2016331314A1 (https=) |
| BR (1) | BR112018006687A2 (https=) |
| CA (1) | CA3000842A1 (https=) |
| CL (1) | CL2018000835A1 (https=) |
| CO (1) | CO2018004576A2 (https=) |
| CR (1) | CR20180246A (https=) |
| EA (1) | EA201890859A1 (https=) |
| HK (1) | HK1259031A1 (https=) |
| IL (2) | IL258476B2 (https=) |
| MX (1) | MX2018004043A (https=) |
| SG (1) | SG10201913953UA (https=) |
| WO (1) | WO2017059451A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011519373A (ja) * | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | ビニル置換脂肪酸 |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| WO2017059451A1 (en) * | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| CA3110680A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| CN111229117B (zh) * | 2018-11-29 | 2022-01-04 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
| CN111229120B (zh) * | 2018-11-29 | 2022-01-07 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
| FR3092968B1 (fr) * | 2019-02-22 | 2021-05-21 | Microphyt | Complement alimentaire |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| WO2021242758A1 (en) * | 2020-05-26 | 2021-12-02 | Imara Inc. | Improved nitro-fatty acid oral dose regimens |
| WO2023014748A1 (en) * | 2021-08-03 | 2023-02-09 | Imara Inc. | Nitrated fatty acids for the treatment of sickle cell disorders |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB587992A (en) | 1944-12-11 | 1947-05-12 | Charles William Scaife | Improvements in and relating to the production of organic nitrogen compounds |
| US3578687A (en) | 1968-01-30 | 1971-05-11 | Texaco Inc | Process for producing 4-nitroalkanoic acids |
| US3819561A (en) | 1970-10-23 | 1974-06-25 | Aerojet General Co | Wetting agents for non-aqueous dispersions |
| JPS5313608B2 (https=) | 1972-06-16 | 1978-05-11 | ||
| JPS5318013B2 (https=) | 1973-03-19 | 1978-06-13 | ||
| US4599430A (en) | 1981-12-21 | 1986-07-08 | The Standard Oil Company | Nitrogenation of hydrocarbons, including the production of maleimide |
| JPS62132804A (ja) | 1985-12-05 | 1987-06-16 | Aguro Kanesho Kk | 植物生長調節剤 |
| US5412137A (en) | 1993-06-07 | 1995-05-02 | Sandoz Ltd. | Process for preparing phosphinyloxy propanaminium inner salt derivatives |
| JPH10507179A (ja) | 1994-10-13 | 1998-07-14 | ペプチド テクノロジー リミテッド | 修飾ポリ不飽和脂肪酸 |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
| GB9618420D0 (en) | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
| US6531150B1 (en) | 1997-10-30 | 2003-03-11 | Morishita Jintan Co., Ltd. | Encapsulated unsaturated fatty acid substance and method for producing the same |
| WO2000009075A2 (en) | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
| AU5319499A (en) | 1999-07-22 | 2001-02-13 | Ivan L. Cameron | Fatty acids to minimize cancer therapy side effects |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
| US6346231B1 (en) | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
| US20010037598A1 (en) | 1999-12-14 | 2001-11-08 | Suppes Galen J. | Process for producing cetane improvers from triglycerides |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
| AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
| AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
| EP1294658B1 (en) | 2000-06-28 | 2005-03-02 | ZAMBON GROUP S.p.A. | Process for the preparation of nitroalkenes |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| JP5026655B2 (ja) | 2001-04-18 | 2012-09-12 | プロメティック、バイオサイエンシーズ、インコーポレーテッド | 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体 |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| EP1407767A4 (en) | 2001-06-18 | 2007-01-24 | Yamada Sachiko | AGONIST MEDICINAL PREPARATIONS PPAR $ G (G) |
| EP1418876A4 (en) | 2001-08-17 | 2007-07-11 | Univ Pittsburgh | ADMINISTRATION OF OSTRADIOL METABOLITES FOR THE TREATMENT OR PREVENTION OF ADIPOSITAS, METABOLIC SYNDROME, DIABETES AND VASCULAR AND KIDNEY DISEASES |
| GB0123961D0 (en) | 2001-10-05 | 2001-11-28 | Astrazeneca Ab | Process and intermediates |
| US20030166716A1 (en) | 2001-11-06 | 2003-09-04 | Serhan Charles N. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
| CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
| EP2384750A1 (en) | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| WO2005016864A1 (en) | 2003-07-29 | 2005-02-24 | The Arizona Disease Control Research Commission | Conjugated nitro alkene anticancer agents based on isoprenoid metabolism |
| US20050136103A1 (en) | 2003-09-17 | 2005-06-23 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| US20090215895A1 (en) | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| US7776916B2 (en) * | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
| RU2527893C2 (ru) | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| EP1772149A1 (en) | 2004-07-27 | 2007-04-11 | Kowa Company. Ltd. | Drug for prevention or treatment of diabetes |
| BRPI0516803A (pt) | 2004-11-19 | 2008-09-23 | Martek Biosciences Corp | oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos |
| WO2006086727A2 (en) | 2005-02-09 | 2006-08-17 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
| US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| WO2008008767A2 (en) | 2006-07-14 | 2008-01-17 | Cedars-Sinai Medical Center | Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer |
| MX2009000657A (es) | 2006-07-19 | 2009-05-28 | Resolvyx Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de mucositis. |
| WO2008103753A2 (en) | 2007-02-20 | 2008-08-28 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
| WO2009017802A1 (en) | 2007-08-01 | 2009-02-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nitro-fattyacid modulation of type ii diabetes |
| CA2699483A1 (en) | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
| WO2009129495A1 (en) | 2008-04-18 | 2009-10-22 | The University Of Utah Research Foundation | Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
| JP2011519373A (ja) | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | ビニル置換脂肪酸 |
| WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
| EP2299997A4 (en) | 2008-06-19 | 2012-01-11 | Univ Utah Res Found | USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US8933255B2 (en) * | 2008-12-31 | 2015-01-13 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
| US8937194B2 (en) | 2008-12-31 | 2015-01-20 | Nitromega Corp. | Topical compositions containing nitro fatty acids |
| US20100286271A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Nitro-alkyl Compound Compositions |
| US20100286272A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications |
| US20100286257A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging |
| JP2013500275A (ja) | 2009-07-29 | 2013-01-07 | フェノメノーム ディスカバリーズ インク | ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用 |
| EP3045167A1 (en) | 2009-07-31 | 2016-07-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Keto fatty acids as anti-inflammatory agents |
| EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
| CA2777455A1 (en) | 2009-11-09 | 2011-05-12 | Novadex Pharmaceuticals Ab | Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| KR20130054249A (ko) * | 2010-03-15 | 2013-05-24 | 울리히 디에츠 | 공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도 |
| EP2568826A4 (en) | 2010-05-13 | 2014-03-26 | Nitromega Corp | NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE |
| US20110319325A1 (en) | 2010-06-28 | 2011-12-29 | Complexa, Inc. | Multi-component pharmaceuticals for treating diabetes |
| WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
| US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
| DE102012008730A1 (de) | 2011-12-02 | 2013-06-06 | Dr. Budz GmbH | Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung |
| WO2013116753A1 (en) | 2012-02-03 | 2013-08-08 | University Of Pittsburgh-Of The Commonwelth System Of Higher Education | Fatty acids as anti-inflammatory agents |
| US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
| CN105339006A (zh) | 2013-05-10 | 2016-02-17 | 尼特罗米加公司 | 含有脂肪酸和亚硝酸盐的营养或膳食补充剂 |
| US20150051283A1 (en) | 2013-06-14 | 2015-02-19 | Complexa, Inc. | Composition and method for inhibition of pkng from mycobacterium tuberculosis |
| WO2015073527A1 (en) | 2013-11-12 | 2015-05-21 | Complexa, Inc. | Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions |
| WO2016161285A1 (en) * | 2015-04-02 | 2016-10-06 | Aobiome Llc | Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria |
| WO2017059451A1 (en) * | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
-
2016
- 2016-10-03 WO PCT/US2016/055206 patent/WO2017059451A1/en not_active Ceased
- 2016-10-03 IL IL258476A patent/IL258476B2/en unknown
- 2016-10-03 HK HK19101519.9A patent/HK1259031A1/zh unknown
- 2016-10-03 CR CR20180246A patent/CR20180246A/es unknown
- 2016-10-03 IL IL297844A patent/IL297844A/en unknown
- 2016-10-03 JP JP2018536704A patent/JP2018529779A/ja not_active Withdrawn
- 2016-10-03 CN CN201680070797.XA patent/CN108430466A/zh active Pending
- 2016-10-03 AU AU2016331314A patent/AU2016331314A1/en not_active Abandoned
- 2016-10-03 CA CA3000842A patent/CA3000842A1/en not_active Abandoned
- 2016-10-03 MX MX2018004043A patent/MX2018004043A/es unknown
- 2016-10-03 BR BR112018006687A patent/BR112018006687A2/pt not_active Application Discontinuation
- 2016-10-03 SG SG10201913953UA patent/SG10201913953UA/en unknown
- 2016-10-03 KR KR1020187012337A patent/KR20180098222A/ko not_active Ceased
- 2016-10-03 CN CN202110744035.6A patent/CN113440506A/zh active Pending
- 2016-10-03 EA EA201890859A patent/EA201890859A1/ru unknown
- 2016-10-03 EP EP16852846.1A patent/EP3355879A4/en not_active Withdrawn
- 2016-10-03 US US15/283,887 patent/US10537541B2/en not_active Expired - Fee Related
-
2018
- 2018-03-29 CL CL2018000835A patent/CL2018000835A1/es unknown
- 2018-04-27 CO CONC2018/0004576A patent/CO2018004576A2/es unknown
-
2019
- 2019-10-18 US US16/657,028 patent/US20200046669A1/en not_active Abandoned
-
2021
- 2021-03-19 US US17/207,380 patent/US20220000824A1/en not_active Abandoned
- 2021-07-14 AU AU2021205027A patent/AU2021205027A1/en not_active Abandoned
- 2021-08-27 JP JP2021139287A patent/JP2021183640A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529779A5 (https=) | ||
| IL297844A (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids | |
| JP2023002662A5 (https=) | ||
| EP3419624B1 (en) | Methods for using fxr agonists | |
| JP2020073546A5 (https=) | ||
| JP2023504415A5 (https=) | ||
| JP2020502250A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP2021119158A5 (https=) | ||
| JP2019515884A5 (https=) | ||
| JP2013521303A5 (https=) | ||
| JP2012520866A5 (https=) | ||
| JP2020535225A5 (https=) | ||
| US12589086B2 (en) | Compositions and methods for the treatment of primary biliary cholangitis | |
| JP2008533127A5 (https=) | ||
| CN116615217A (zh) | 炎症性疾病和/或疼痛性疾病的预防或治疗药 | |
| JP2015508068A5 (https=) | ||
| JP7523691B2 (ja) | 急性膵炎を予防及び治療するための薬物の製造におけるノルハルマンの使用 | |
| JP2019218379A5 (https=) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| WO2019053582A1 (en) | COMBINATIONS HAVING FXR AGONISTS | |
| TW201811372A (zh) | 利用fxr促效劑之方法 | |
| JP2019507786A5 (https=) | ||
| KR20210110407A (ko) | Fxr 작용제의 신규 요법 | |
| Christopoulou et al. | Hyponatremia in patients with heart failure beyond the neurohormonal activation associated with reduced cardiac output: A holistic approach |